Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
168 Cards in this Set
- Front
- Back
the relationship of the physical-chemical properties of a drug to its bioavailability, pharmacokinetics, pharmacodynamic and toxicologic effects? |
biopharmaceutics |
|
a drug product that has the same bioavailability as the reference product when administered at the same molar dose of active drug and by the same route of administration? |
bioequivalence |
|
drug products that contain the same active drug in the same chemical form (salt, ester, etc.). The drug products must be the same dosage form, same strength or concentration, and be administered by the same route of administration? |
pharmaceutical equivalents |
|
drug products that are both bioequivalent and pharmaceutical equivalents and that produce the same therapeutic effects? |
therapeutic equivalents |
|
the modeling of movement of a drug's time course within the body and describes the process of drug disposition or ADME? |
pharmacokinetics |
|
relates the concentration at the site of action to the nature and magnitude of the observed effects? |
pharmacodynamics |
|
The PK and PD of a drug determine? |
relationship between administration of dose and therapeutic response to dose |
|
what kind of an approach does pharmacokinetics provide to drug dosing? |
rational |
|
Process by which unchanged drug proceeds from the site of administration to the site of measurement in the body? |
administration |
|
process of reversible transfer of a drug to and from the site of measurement? |
distribution |
|
process of biotransformation from the parent drug to one or more metabolites? |
metabolism |
|
irreversible loss of drug from the site of measurement? |
elimination |
|
the entire dose administered can be accounted for by the drug and its metabolites in various body compartments and as excreted drug or metabolite is an example of? |
mass balance principles |
|
exponential decline in plasma concentration and dependence on distribution and elimination of a drug is indicative of an? |
IV dose |
|
maximum plasma concentrations of a drug? |
Cmax |
|
time to maximum plasma concentration? |
tmax |
|
Cmax, tmax, and AUC are indicative of? |
oral dose |
|
which routes of administration does absorption account for? |
all extravascular routes (all but IV) |
|
what absorption properties need to be considered in relation to movement of drug from administration site into systemic circulation? |
rate and extent |
|
can change gastric emptying, drug stability, dissolution, binding of drugs in the GI tract, and first-pass effect? what does this affect? |
food/herbal products/drugs, rate and extent of absorption |
|
permeability of a drug across lipid bilayers and dissolution of a compound from formulation are both affected by? |
ionization and lipophilicity |
|
driving force for passive diffusion? |
concentration gradient |
|
does not actively participate in absorption? |
membrane |
|
passive diffusion can be? |
transcellular or paracellular |
|
permeability across the membrane is dependent on? |
size, protein binding, lipophilicity, charge |
|
increased lipophilicity (decreased polarity)=? |
increased permeability |
|
higher partition coefficient means? |
increased partitioning into octanol (lipid) and less into water |
|
also remember to consider (?) when thinking about permeability? |
size |
|
only (ionized or non-ionized) compounds cross membranes? |
non-ionized |
|
ionization and permeability for weak acids: ↓ pH (more acidic) → ↑ % HA → ↑ non-ionized →? |
↑ absorption rate |
|
ionization and permeability for weak bases: ↑ pH (more basic) → ↑ % R3N → ↑ non-ionized →? |
↑ absorption rate |
|
ionization and dissolution for weak acids: ↑ pH → ↑ % ionized → ↑ solubility →? |
↑ dissolution rate |
|
ionization and dissolution for weak bases: ↓ pH → ↑ % ionized → ↑ solubility →? |
↑ dissolution rate |
|
physiochemical properties that favor drug dissolution? |
do not favor permeability across membranes, and vice versa |
|
BCS means? |
biopharmaceutics classification system |
|
high solubility & high membrane permeability? |
generally well absorbed |
|
high solubility & low membrane permeability? |
permeability rate limited absorption |
|
low solubility & high membrane permeability? |
dissolution rate-limited absorption |
|
low solubility & low membrane permeability? |
very poor oral bioavailability and therefore poor absorption |
|
proteins incorporated into the lipid bilayer that transport substances from one side of the membrane to another? |
carrier mediated transport |
|
what kind of substances use carrier mediated transport? |
lipid-insoluble substances that are too large for passive diffusion (i.e. amino acids and sugars) |
|
substrate specific, saturable, and subject to inhibition? |
transporters |
|
two types of transporters? |
uptake or efflux |
|
does passive facilitated diffusion require energy? |
no |
|
what does passive facilitated diffusion use as its driving force? |
concentration gradient |
|
no more than an equal concentration can be attained on the receiving side of the membrane in which type of transport? |
passive facilitated diffusion |
|
transport that requires energy? |
active transport |
|
molecules transported against concentration gradient in? |
active transport |
|
examples of primary active transport? |
Na/K ATPase and drug transporters that use ATP |
|
examples of secondary active transport? |
antiporters and symporters |
|
gastric emptying and intestinal motility affects? |
absorption |
|
food affects? |
absorption |
|
other medications and supplements can change absorption via? |
pH changes, binding to drugs, effects of first-pass metabolism |
|
can compliance affect absorption? |
yes |
|
refers the the fraction of the dose administered that reaches systemic circulation? |
bioavailability |
|
accounts for absorption from the gut (or other site of administration) and first-pass effects in the intestine and liver (transport and metabolism)? |
bioavailability |
|
most appropriate parameter to measure bioavailability? |
AUC |
|
measure of total systemic exposure? |
AUC |
|
a measure of the total amount of a drug that reaches systemic circulation from a dosage form compared to a reference standard? |
relative bioavailability |
|
when is relative bioavailability used? |
when no IV data available |
|
what prevents availability of IV formulation? |
cost, instability, poor solubility, adverse effects, lack of approval |
|
can be used to compare the fraction absorbed for different dosage forms, routes of administration, or different conditions? |
relative bioavailability |
|
bioequivalence testing for generics vs. brand drugs? |
relative bioavailability |
|
bioavailability data can be used for determining? |
quantity absorbed, rate of absorption, duration of drug presence, relationship between levels and efficacy/toxicity |
|
what must be either pharmaceutical equivalents or pharmaceutical alternatives (same therapeutic moiety or its precursor, but not necessarily the same amount, dosage form, salt or ester)? |
bioequivalent drug products |
|
To be bioequivalent, two such products must? |
exhibit similar rates and extents of absorption when same molar dose administered |
|
some products may be considered bioequivalent when only? why? |
extents of absorption are similar, because rate might not be a factor in effectiveness |
|
the reversible transfer of drug between the vascular space and the extravascular space? |
distribution |
|
Volume of Distribution (Vd) represents? |
specific dilution space of the drug in the body |
|
different drugs have different volumes of distribution reflecting? |
tissue distribution vs. plasma concentration |
|
blood is 55%? |
plasma |
|
most plasma proteins are? |
albumin |
|
the space between the cells in a tissue? |
interstitium |
|
interstitial fluid make-up? |
plasma proteins and water |
|
how much interstitial fluid in a 70 kg person? |
~ 9 liters |
|
interstitial fluid that carries lipophilic compounds/drugs and is very slow? |
lymph |
|
how much plasma in a 70 kg person? |
~ 3 liters |
|
combination of interstitial fluid and plasma? |
extracellular fluid (ECF) |
|
solutes and fluid found inside cell? |
intracellular fluid (ICF) |
|
volume of total body water in 70 kg person? |
42 liters |
|
range of volume of drugs in humans? |
3 L (0.04 L/kg) - 1400 L (20 L/kg) |
|
not a true physiologic volume? |
apparent volume of distribution |
|
apparent volume (Vd) describes? |
drug concentration in tissues relative to plasma |
|
increased Vd? |
more distribution into tissues, less in plasma |
|
decreased Vd? |
less distribution into tissues, more in plasma |
|
size that easily moves through paracellular gaps of capillaries (except the brain)? |
MW less than 10,000 |
|
size that is too large to enter ISF in significant amounts? |
MW more than 10,000 |
|
drugs can bind to which two plasma proteins? |
albumin and alpha-1-acid-glycoprotein |
|
well perfused tissues? why is this significant? |
brain, liver, kidney, heart, more perfusion means better distribution |
|
disease states affecting perfusion? |
hypertension, heart failure, diabetes |
|
why is plasma protein binding relevant? |
only free drug can pass through capillary endothelium |
|
binding and accumulation in tissues can affect? |
distribution |
|
which drug state mainly uses paracellular movement? |
ionized |
|
two main processes of elimination of drug from the body? |
metabolism, excretion |
|
chemical transformation of drug into metabolites? |
metabolism |
|
removal of unchanged drug (primarily by via the kidneys)? |
excretion |
|
organs responsible for elimination? |
liver, kidney |
|
metabolism and biliary secretion? |
liver |
|
filtration, secretion, reabsorption? |
kidney |
|
responsible for removal of metabolic waste and for maintaining fluid and electrolyte balance in the body? |
kidney |
|
about how many nephrons per kidney? |
~ 1 million |
|
why is there a gradual decrease in number of nephrons as people age? |
nephrons cannot regenerate |
|
functional subunit of the kidney? |
nephron |
|
urine formation and renal clearance result from three processes? |
glomerular filtration, tubular secretion, tubular reabsorption GTT |
|
order of renal clearance by anatomy? |
filtration, secretion, reabsorption |
|
for drugs, most clearance occurs at the? |
glomerulus and proximal tubule (early in the nephron) |
|
most important organ for drug metabolism? |
liver |
|
metabolism is important for both? |
elimination and absorption |
|
liver structures that allow for maximum drug intake? |
sinusoids, hepatocytes |
|
the liver removes drugs and other substances from the (?) for metabolism |
portal vein, arterial blood |
|
drugs in the liver can also be secreted into (?) via what mechanism? |
bile, active transport |
|
drugs secreted into the bile are emptied into the? |
duodenum |
|
in the intestines, certain bile salts and lipids (and drugs) are reabsorbed back into the blood through a process called? |
enterohepatic recirculation |
|
elimination of drug from the body is described by? |
clearance (CL) |
|
measure of efficiency of removal of drug by all eliminating organs (metabolism, transport, excretion, etc.)? |
clearance |
|
volume of plasma cleared of drug per unit time? |
clearance |
|
a combination of all elimination process? |
clearance |
|
CL NR means |
non-renal clearance |
|
urine pH affects? |
renal clearance |
|
inhibition of secretion/reabsorption of drugs affects? |
renal clearance |
|
enzyme and transporter inhibition/induction affects? |
hepatic clearance |
|
genetic variability of enzymes and transporters affects? |
hepatic clearance |
|
blood flow, plasma protein binding, disease states all generally affect? |
clearance |
|
minimum drug concentration necessary to cause a pharmacological response? |
minimum effective concentration (MEC) |
|
minimum drug concentration necessary to cause a toxic or adverse response? |
minimum toxic concentration (MTC) |
|
drug concentration range between the MEC and MTC? |
therapeutic window |
|
time from drug administration until the MEC? |
onset time |
|
time that drug concentration remains above the MEC? |
duration of action |
|
amount of drug that produces the desired pharmacological effect in 50% of individuals tested? |
median effective dose (ED50) |
|
amount of drug that produces a defined toxic or adverse effect in 50% of individuals tested? |
median toxic dose (TD50) |
|
ratio between the drug’s median toxic dose and median effective dose; quantifies the relationship between the desired and undesired effects of the drug? |
therapeutic index (TD50/ED50)
|
|
defines the optimal drug concentration range for therapeutic success? |
therapeutic window |
|
concentrations below or above therapeutic window will lead to? |
therapeutic failure |
|
MSC means? |
maximum safe concentration |
|
dependent on route of administration, absorption, distribution to target sites, dose, and exposureresponserelationship? |
time to onset |
|
integration of (?) is important? |
PK and PD |
|
after a dose, an effect begins when concentration at target site reaches? |
a critical value |
|
total contribution of atoms in a molecule or components in a solution i.e. molecular weight and mass |
additive property of solutions |
|
depends on structural arrangement of the atoms within a molecule i.e. optical rotation |
constitutive property of solutions |
|
depends on the number of particles in solution i.e. vapor pressure lowering, freezing point depression, boiling point elevation, osmotic pressure |
colligative property of solutions |
|
colligative properties are dependent on? |
mole fraction (X), molality (m), and osmolality molarity and osmolarity for convenience |
|
disadvantage to molarity? |
volume changes with temperature and mixing |
|
used for theoretical work i.e. development of colligative properties |
molality |
|
you know exactly how much solute and solvent is an advantage of? |
molality |
|
not useful for practical applications since its much easier to measure volume |
molality |
|
X1 + X2 always =? |
1 |
|
number of moles of one constituent divided by the total number of moles of both solute and solvent? |
mole fraction |
|
measure of the chemical activity of an electrolyte? |
equivalent |
|
number of equivalents per liter? |
normality |
|
dissolve in water yielding ions? |
electrolytes |
|
do not yield ions in solution? |
non-electrolytes |
|
what to think about when it comes to equivalence? |
valence |
|
solid solute does not exhibit this, only volatile liquids do? |
vapor pressure |
|
causes some molecules of a solvent to leave the solution and enter the vapor phase? |
escaping tendency |
|
what happens to vapor pressure when two liquids are mixed? |
vapor pressure of each liquid is reduced in proportion to its mole fraction |
|
states that vapor pressure of a component (rho) equals the mole fraction of the component in mixture times the vapor pressure of the pure component? |
Raoult's Law |
|
vapor pressure equals external pressure at the? |
boiling point |
|
adding solute (?) vapor pressure and (?) boiling point? |
decreases, increases |
|
kb for water? |
0.51 |
|
change in boiling point is proportional to the mole fraction (molality) of (?) in the solution? |
solute |
|
when solute is added to the solution, the escaping tendency and vapor pressure of a solution are (?) and this (?) freezing point? |
reduced, decreases |
|
kf for water is? |
1.86 |
|
osmotic pressure principle? |
solvent follows more solute |
|
used to calculate osmotic pressure? |
ideal gas law |
|
R (gas constant) value? |
0.082 |
|
celsius to kelvin? |
add 273 |
|
n/V = m only in? |
cases of dilute solutions |
|
used to adjust colligative properties for solutions of electrolytes? |
van't Hoff factor (i) |